Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates

Nawal Al Kaabi (), Abderrahim Oulhaj, Subhashini Ganesan, Farida Ismail Al Hosani, Omer Najim, Halah Ibrahim, Juan Acuna, Ahmed R. Alsuwaidi, Ashraf M. Kamour, Ashraf Alzaabi, Badreyya Ahmed Al Shehhi, Habiba Al Safar, Salah Eldin Hussein, Jehad Saleh Abdalla, Dalal Saeed Naser Al Mansoori, Ahmed Abdul Kareem Al Hammadi, Mohammed A. Amari, Ahmed Khamis Al Romaithi, Stefan Weber, Santosh Elavalli, Islam Eltantawy, Noura Khamis Alghaithi, Jumana Nafiz Al Azazi, Stephen Geoffrey Holt, Mohamed Mostafa, Rabih Halwani, Hanif Khalak, Wael Elamin, Rami Beiram and Walid Zaher
Additional contact information
Nawal Al Kaabi: Sheikh Khalifa Medical City SEHA
Abderrahim Oulhaj: Khalifa University
Subhashini Ganesan: G42 Healthcare, Masdar City
Farida Ismail Al Hosani: Abu Dhabi Public Health Center – ADPHC
Omer Najim: Department of Health (DOH)
Halah Ibrahim: Khalifa University
Juan Acuna: Khalifa University
Ahmed R. Alsuwaidi: United Arab Emirates University
Ashraf M. Kamour: Sheikh Khalifa Medical City SEHA
Ashraf Alzaabi: United Arab Emirates University
Badreyya Ahmed Al Shehhi: Abu Dhabi Public Health Center – ADPHC
Habiba Al Safar: Khalifa University of Science and Technology
Salah Eldin Hussein: Sheikh Khalifa Medical City SEHA
Jehad Saleh Abdalla: Sheikh Khalifa Medical City SEHA
Dalal Saeed Naser Al Mansoori: Tawam hospital SEHA
Ahmed Abdul Kareem Al Hammadi: Tawam hospital SEHA
Mohammed A. Amari: Sheikh Khalifa Medical City SEHA
Ahmed Khamis Al Romaithi: Sheikh Khalifa Medical City SEHA
Stefan Weber: Reference Laboratory for Infectious Diseases (RLID) and Union 71
Santosh Elavalli: G42 Healthcare, Masdar City
Islam Eltantawy: IROS (Insights Research Organization & Solutions)
Noura Khamis Alghaithi: Ambulatory Health Services- SEHA
Jumana Nafiz Al Azazi: Abu Dhabi Health Services Company- SEHA
Stephen Geoffrey Holt: SEHA Kidney Care, SEHA, Abu Dhabi Health Services Company
Mohamed Mostafa: Clinical research organization
Rabih Halwani: University of Sharjah
Hanif Khalak: G42 Healthcare, Masdar City
Wael Elamin: G42 Healthcare, Masdar City
Rami Beiram: United Arab Emirates University
Walid Zaher: Khalifa University

Nature Communications, 2022, vol. 13, issue 1, 1-9

Abstract: Abstract The effectiveness of the inactivated BBIBP-CorV vaccine against severe COVID-19 outcomes (hospitalization, critical care admission and death due to COVID-19) and its long-term effectiveness have not been well characterized among the general population. We conducted a retrospective cohort study using electronic health records of 3,147,869 adults, of which 1,099,886 vaccinated individuals were matched, in a 1:1 ratio to 1,099,886 unvaccinated persons. A Cox-proportional hazard model with time varying coefficients was used to assess the vaccine effectiveness adjusting for age, sex, comorbidity, ethnicity, and the calendar month of entry into the study. Our analysis showed that the effectiveness was 79.6% (95% CI, 77.7 to 81.3) against hospitalization, 86% (95% CI, 82.2 to 89.0) against critical care admission, and 84.1% (95% CI, 70.8 to 91.3) against death due to COVID-19. The effectiveness against these severe outcomes declined over time indicating the need for booster doses to increase protection against severe COVID-19 outcomes.

Date: 2022
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-022-30835-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30835-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-30835-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().